Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | GAA | P10253 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172201 | 1.00 | MAPT (0.70) | MAPTKMT2AGAAKDM4ENOX1 | |
| SCHEMBL4747962 | 0.94 | CA1 (0.64) | MAPTKMT2AGAAKDM4ENOX1 | |
| SCHEMBL4747964 | 0.94 | CA1 (0.64) | MAPTKMT2AGAAKDM4ENOX1 | |
| SCHEMBL2681914 | 0.84 | RAB9A (0.74) | MAPTKMT2AGAAKDM4ENOX1 | |
| SCHEMBL15972775 | 0.84 | MAPT (0.59) | MAPTKMT2AGAAKDM4ERAB9A | |
| SCHEMBL15972778 | 0.84 | MAPT (0.59) | MAPTKMT2AGAAKDM4ERAB9A | |
| SCHEMBL23928498 | 0.82 | MAPT (0.50) | MAPTKMT2AGAAKDM4ENOX1 | |
| SCHEMBL16039805 | 0.81 | RAB9A (0.62) | MAPTKMT2AGAAKDM4ERAB9A | |
| SCHEMBL16039803 | 0.81 | RAB9A (0.62) | MAPTKMT2AGAAKDM4ERAB9A | |
| SCHEMBL2644905 | 0.81 | CYP1A2 (0.71) | MAPTKMT2AGAAKDM4ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160032257-A1 | AGENT AND METHOD FOR MODIFYING THE 5' CAP OF RNA | UNIVERSITAET HAMBURG (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160032257-A1 | AGENT AND METHOD FOR MODIFYING THE 5' CAP OF RNA | UNIVERSITAET HAMBURG (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2014090246-A1 | AGENT AND METHOD FOR MODIFYING THE 5' CAP OF RNA | UNIVERSITÄT HAMBURG (DE) | 2014-06-19 | — | — | WO | disclosed |
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | CYP3A4, CYP4B1, CYP2E1 | MAPT 1343/4885KMT2A 3690/4885GAA 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.